<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575702</url>
  </required_header>
  <id_info>
    <org_study_id>CG04043028</org_study_id>
    <nct_id>NCT03575702</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.</brief_title>
  <official_title>International, Multicenter, Open-label, Randomized, Comparative Clinical Study of Efficiency and Safety of Medicinal Product Uritos® (Imidafenacin, Film-coated Tablets; 0,1 mg, Kyorin Pharmaceutical Co. Ltd, Japan) and Urotol® (Tolterodine, Film-coated Tablets 2 mg, Zentiva k.s., Czech Republic) for Treatment of Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synergy Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study was confirmation on non-inferiority and validation of similar safety
      profile of new anti-muscarinic medicinal product Uritos® (Imidafenacin) in comparison with
      other product from m-cholinergic antagonists group Urotol® (Tolterodine).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess clinical efficiency and safety of Uritos® (Imidafenacin) in comparison to Urotol®
      (Tolterodine) according to its influence on urination frequency and number of urinary
      incontinence episodes a total of 327 patients underwent screening and 300 patients were
      randomized (150 patients in the Uritos® group and 150 patients in the Urotol® group).
      Screening period was not exceeding 2 weeks (14 days). Therapy was performed during 12 weeks
      (84 days). Every patient received only one treatment (Uritos® or Urotol®) during the
      treatment period. Patients were returning to the trial site to assessment visits on Weeks 2,
      4, 8 and 12 with permissible variation ± 3 days. Observation period after the end of
      treatment - 30 ± 5 days (could be performed through telephone connection without need for
      physician appointment by patient). Maximum observation period: 136 days.

      Efficacy and safety parameters were assessed as per primary and secondary endpoints.

      The results of this study could potentially provide new optimum approaches to OAB treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Mean Daily Number of Urination Episodes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The mean daily number of urination episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Daily Number of Incontinence Episodes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Daytime Number of Incontinence Episodes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The mean daytime number of incontinence episodes was calculated as the total number of episodes from 7 am to 11 pm for the study period (between visits) divided by the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Nighttime Number of Incontinence Episodes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The mean nighttime number of incontinence episodes was calculated as the total number of episodes from 11 pm to 7 am for the study period (between visits) divided by the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Number of Incontinence Episodes at Week 2, 4 and 8</measure>
    <time_frame>Baseline and Week 2, 4 and 8</time_frame>
    <description>Separately for daily, daytime and nighttime measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Weekly Number of Incontinence Episodes at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The mean weekly number of incontinence episodes was calculated as the total number of episodes per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of weeks in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Daily Number of Urination Episodes at Week 2, 4 and 8 Visit as Compared to the Treatment Initiation Visit</measure>
    <time_frame>Baseline and Week 2, 4 and 8</time_frame>
    <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Overactive Bladder Symptom Score According to Overactive Bladder (OAB) Awareness Tool Questionnaire at 2, 4, 8 and 12 Week</measure>
    <time_frame>Baseline and Week 2, 4, 8 and 12</time_frame>
    <description>Overactive bladder (OAB) Awareness Tool Questionnaire (version OAB-V8, containing 8 questions) is a validated questionnaire. Patient is asked to answer 8 questions concerning typical symptoms of OAB giving answers with a scale with minimum - 0 score defined as &quot;no bothering at all&quot; and maximmum - 5 score defined as &quot;a very big deal&quot; to assess the severity of these symptoms. All answers are simply summed to make a combined final score. Male participants should add 2 points to their final score. The final scores range from 0 to 40 (for women) and 42 (for men). The score equal to 8 and more is interpreted as high probability of OAB presence, with the higher scores indicating more bothersome symptoms of OAB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EQ-5D-based Quality of Life at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Euro Quality of Life five Dimensions questionnaire ( EQ-5D, version EQ-5D-5L) is a validated questionnaire for the assessment of health-related quality of life. It consists of a questionnaire and a visual analogue scale (EQ-VAS). The self-assessment questionnaire is self-reported description of the subject's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The subject is asked to assess their own current level of function in each dimension by 5-level scale from &quot;no problems&quot; to &quot;significant problem&quot; grades. The EQ-VAS is a self-rated health status using a VAS in mm from 0 (the worse health status) to 100 (the best health status). The EQ-VAS records the subject's perceptions of their own current overall health quantitatively in mm and can be used to monitor changes with time. The results of patients assessment by VAS are presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 35 days after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the Volume of Residual Urine</measure>
    <time_frame>Baseline and Week 4, 8 and 12</time_frame>
    <description>Measured via the urine bladder ultrasound (US)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Clinically Significant Changes in Laboratory Parameters</measure>
    <time_frame>Week 8 and 12</time_frame>
    <description>Including blood chemistry, blood count and urinalysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Clinically Significant Changes in ECG Parameters</measure>
    <time_frame>Week 12 of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Clinically Significant Vital Signs Changes</measure>
    <time_frame>Week 12 of treatment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Uritos®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urotol®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uritos®</intervention_name>
    <description>film-coated tablets 0.1 mg</description>
    <arm_group_label>Uritos®</arm_group_label>
    <other_name>Imidafenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urotol®</intervention_name>
    <description>film coated tablets, 2 mg</description>
    <arm_group_label>Urotol®</arm_group_label>
    <other_name>Tolterodine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed dated informed consent.

          2. Confirmed overactive bladder (OAB). The OAB diagnosis was made based on characteristic
             symptoms of the patient:

               1. urinary incontinence - 5 or more episodes a week;

               2. frequent urination - 8 or more times a day;

               3. imperative urination urge - 1 or more episodes a day.

          3. The duration of the presence of OAB symptoms is 3 months or more (the assessment is
             based on patient's history and medical records).

          4. Overactive bladder Awareness Tool Questionnaire (OAB Awareness Tool) score 8 and more
             at the screening visit and randomization visit.

          5. Negative result of the urine pregnancy test at the screening and the randomization
             visit before receiving the first dose of the study drug in women of childbearing
             potential.

          6. Female patients of childbearing potential and male patients and their female partners
             should use at least two birth control methods, one of those is barrier, during the
             entire study period and for at least 35 days following administration of the last dose
             of the study product. Acceptable methods of contraception:

               -  oral, transdermal, implantation or injection hormone therapy;

               -  effective intrauterine devices;

               -  double barrier contraceptive methods.

          7. Willingness and ability to follow the study visits schedule, treatment plan,
             laboratory tests and other study procedures.

        Exclusion Criteria:

          1. A history of hypersensitivity or suspected hypersensitivity to tolterodine or
             imidafenacin.

          2. Structural abnormalities of the bladder, including bladder cancer, bladder stones,
             interstitial cystitis.

          3. The volume of residual urine is 100 ml or more with bladder ultrasound.

          4. Documented diagnosis of stress urinary incontinence.

          5. Operative interventions on the bladder or urethra within the previous 6 months or
             indications for surgical treatment for OAB.

          6. Exacerbation of gynecological diseases including endometriosis, uterine leiomyoma
             exceeding 3 cm in diameter.

          7. Prostate cancer.

          8. Prostate diseases with clinically significant urodynamics abnormality (benign
             prostatic hyperplasia, acute and chronic prostatitis, prostatic calculus).

          9. Renal and urinary inflammatory disorders (pyelonephritis, bacterial cystitis,
             urethritis).

         10. For male, the prostatic specific antigen (PSA) level above 4 ng/mL.

         11. Severe liver impairment alanine aminotransferase (ALT) and/or aspartate
             aminotransferase (AST) level 3 and more times exceeding the upper limit of normal
             and/or total bilirubin level 1.5 times exceeding the upper limit of normal.

         12. Moderate or severe renal impairment based on the medical records and/or glomerular
             filtration rate &lt; 50 mL/min determined by Cockroft-Gault formula and/or blood
             creatinine level &gt; 133 μmol/L at screening.

         13. A positive test result for hepatitis B, hepatitis C and human immunodeficiency virus
             (HIV).

         14. Patients suffering from a neoplastic condition without remission at least within 5
             years from the start of administration of the study product.

         15. Vascular dementia, dementia in Alzheimer's disease, dementia in other diseases,
             including organic amnestic syndrome.

         16. Parkinson's disease or secondary parkinsonism.

         17. Nonspecific ulcerative colitis, including severe ulcerative colitis.

         18. Thyroid disorders with hyperthyroidism signs.

         19. Chronic heart insufficiency Stage III-IV by New York Heart Association Chronic heart
             insufficiency classification (NYHA).

         20. Hypotension: systolic blood pressure (SBP) &lt; 90 mm Hg and/or diastolic blood pressure
             (DBP) &lt; 60 mm Hg.

         21. Uncontrolled medically induced hypertension.

         22. Hemodynamically and/or clinically significant heart arrhythmias.

         23. QTc prolongation up to 450 ms and more in men and 470 ms and more in women.

         24. Open-angle glaucoma.

         25. Myasthenia gravis.

         26. Megacolon, paralytic ileus, pyloric part of the stomach/duodenal occlusion and any
             other conditions associated with clinically significant gastric/intestinal obstruction
             or depressed motility.

         27. Necessity of intake and/or intake of prohibited products listed in the Section
             &quot;Acceptable and prohibited recent and concomitant therapy&quot; within 7 days before the
             start of therapy.

         28. Drug abuse, chronic alcoholism, any psychotic disorders.

         29. Participation in other studies within 3 months prior to the beginning of the current
             study and/or during participation in this study.

         30. Pregnancy and/or breastfeeding.

         31. Female patients of childbearing potential, having an unprotected sexual contact with a
             male person non-sterilized by vasectomy during at least 6 months, within 14 days
             before administration of the study product.

         32. Inability to follow protocol procedures.

         33. Any other acute or exacerbation and/or decompensation of chronic diseases at inclusion
             in the study.

         34. Patient's behavior, any safety reasons, clinical and administrative reasons, which,
             according to Investigator's opinion, may potentially affect the study drug
             safety/efficiency assessment.

         35. Other medical and psychiatric conditions or deviations of laboratory parameter which
             may increase patient risk associated with participation in the study or administration
             of the study product, or which can influence the interpretation of the study results
             and, according to Investigator's opinion, make a person ineligible for participation
             in this study.

         36. Patients who are employees of the study site or patients who are employees of the
             Sponsor/Contract Research Organization (CRO), directly involved in this clinical
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Family polyclinic №4, LLC</name>
      <address>
        <city>Korolev</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.I. Evdokimov Moscow State University of Medicine and Dentistry, Municipal Clinical Hospital named after Spasokukotskiy S.I</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.I. Pirogov Russian National Research University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Radiological Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National N.I. Pirogov Medical and Surgical Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All-Russian A.M. Nikiforov Center for Emergency and Radiation Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baltic Medicine LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.P. Pavlov First St. Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrKli Hospital, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State-Funded Healthcare Institution St. Luka Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <results_first_submitted>August 20, 2018</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2019</results_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>frequent urination</keyword>
  <keyword>urge incontinence</keyword>
  <keyword>urgency episodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03575702/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrollment was conducted in 11 clinical sites in Russia between July 2016 and April 2017. After the screening period 300 patients (150 in each group) were included in the study. 299 patients started study treatments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Uritos®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
        </group>
        <group group_id="P2">
          <title>Urotol®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Uritos®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
        </group>
        <group group_id="B2">
          <title>Urotol®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="13.50"/>
                    <measurement group_id="B2" value="46.1" spread="13.54"/>
                    <measurement group_id="B3" value="46.6" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Calculated as patient's weight (kg) / height (m^2)</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="5.48"/>
                    <measurement group_id="B2" value="25.8" spread="5.33"/>
                    <measurement group_id="B3" value="25.8" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Mean Daily Number of Urination Episodes at Week 12</title>
        <description>The mean daily number of urination episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Daily Number of Urination Episodes at Week 12</title>
          <description>The mean daily number of urination episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>urination episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.5"/>
                    <measurement group_id="O2" value="11.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.0"/>
                    <measurement group_id="O2" value="8.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="3.0"/>
                    <measurement group_id="O2" value="-3.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that effect of Urotol according to the assessment of mean daily urination episodes exceeds effect of Uritos.
A sample containing of 222 patients (111 per study group) is considered sufficient to prove the alternative hypothesis at the significance level 0.025% and study power 80%. Given the expected drop out rate during the treatment period, the total number of patients to be randomized is 300 (150 in each group).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is considered as change in mean daily urination episodes of 0,8 episodes per day</non_inferiority_desc>
            <p_value>=0.5595</p_value>
            <method>ANCOVA</method>
            <method_desc>The number of urination episodes at the initiation of therapy is used as covariate, and the therapy group is used as a factor.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Daily Number of Incontinence Episodes at Week 12</title>
        <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Daily Number of Incontinence Episodes at Week 12</title>
          <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>incontinence episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.4"/>
                    <measurement group_id="O2" value="2.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                    <measurement group_id="O2" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="2.2"/>
                    <measurement group_id="O2" value="-1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0008</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Daytime Number of Incontinence Episodes at Week 12</title>
        <description>The mean daytime number of incontinence episodes was calculated as the total number of episodes from 7 am to 11 pm for the study period (between visits) divided by the number of days in the period.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Daytime Number of Incontinence Episodes at Week 12</title>
          <description>The mean daytime number of incontinence episodes was calculated as the total number of episodes from 7 am to 11 pm for the study period (between visits) divided by the number of days in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>daytime incontinence episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.9"/>
                    <measurement group_id="O2" value="1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.7"/>
                    <measurement group_id="O2" value="-1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0099</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Nighttime Number of Incontinence Episodes at Week 12</title>
        <description>The mean nighttime number of incontinence episodes was calculated as the total number of episodes from 11 pm to 7 am for the study period (between visits) divided by the number of days in the period.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Nighttime Number of Incontinence Episodes at Week 12</title>
          <description>The mean nighttime number of incontinence episodes was calculated as the total number of episodes from 11 pm to 7 am for the study period (between visits) divided by the number of days in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>nighttime incontinence episode per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.8"/>
                    <measurement group_id="O2" value="0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.8"/>
                    <measurement group_id="O2" value="-0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Number of Incontinence Episodes at Week 2, 4 and 8</title>
        <description>Separately for daily, daytime and nighttime measurements.</description>
        <time_frame>Baseline and Week 2, 4 and 8</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Number of Incontinence Episodes at Week 2, 4 and 8</title>
          <description>Separately for daily, daytime and nighttime measurements.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>incontinence episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline number of daily incontinence episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.4"/>
                    <measurement group_id="O2" value="2.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daily incontinence episodes (week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.8"/>
                    <measurement group_id="O2" value="-1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daily incontinence episodes (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.0"/>
                    <measurement group_id="O2" value="-1.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daily incontinence episodes (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.0"/>
                    <measurement group_id="O2" value="-1.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline number of daytime incontinence episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.9"/>
                    <measurement group_id="O2" value="1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daytime incontinence episodes (week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.3"/>
                    <measurement group_id="O2" value="-1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daytime incontinence episodes (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.5"/>
                    <measurement group_id="O2" value="-1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in daytime incontinence episodes (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.5"/>
                    <measurement group_id="O2" value="-1.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline number of nightime incontinence episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.8"/>
                    <measurement group_id="O2" value="0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in nighttime incontinence episodes (week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.6"/>
                    <measurement group_id="O2" value="-0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in nighttime incontinence episodes (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.8"/>
                    <measurement group_id="O2" value="-0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in nighttime incontinence episodes (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in number of daily incontinence episodes - week 2</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0236</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in number of daily incontinence episodes - week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in number of daily incontinence episodes - week 8</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in daytime number of daily incontinence episodes - week 2</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.3835</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in daytime number of daily incontinence episodes - week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0088</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in daytime number of daily incontinence episodes - week 8</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in nighttime number of daily incontinence episodes - week 2</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in nighttime number of daily incontinence episodes - week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in nighttime number of daily incontinence episodes - week 8</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Weekly Number of Incontinence Episodes at Week 12</title>
        <description>The mean weekly number of incontinence episodes was calculated as the total number of episodes per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of weeks in the period.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Weekly Number of Incontinence Episodes at Week 12</title>
          <description>The mean weekly number of incontinence episodes was calculated as the total number of episodes per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of weeks in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>incontinence episodes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="16.8"/>
                    <measurement group_id="O2" value="16.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.5"/>
                    <measurement group_id="O2" value="3.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="15.3"/>
                    <measurement group_id="O2" value="-13.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Daily Number of Urination Episodes at Week 2, 4 and 8 Visit as Compared to the Treatment Initiation Visit</title>
        <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
        <time_frame>Baseline and Week 2, 4 and 8</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Daily Number of Urination Episodes at Week 2, 4 and 8 Visit as Compared to the Treatment Initiation Visit</title>
          <description>The mean daily number of incontinence episodes was calculated as the total number of episodes (on the basis of the data that patients entered into their diaries) per day (from 7 am to 7 am the next day) for the study period (between visits) divided by the number of days in the period.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>urination episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.5"/>
                    <measurement group_id="O2" value="11.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="2.9"/>
                    <measurement group_id="O2" value="10.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.6"/>
                    <measurement group_id="O2" value="-1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="2.7"/>
                    <measurement group_id="O2" value="9.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.7"/>
                    <measurement group_id="O2" value="-2.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="2.7"/>
                    <measurement group_id="O2" value="8.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.9"/>
                    <measurement group_id="O2" value="-3.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.1348</p_value>
            <method>ANCOVA</method>
            <method_desc>Week 2 changes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.3199</p_value>
            <method>ANCOVA</method>
            <method_desc>Week 4 changes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.9537</p_value>
            <method>ANCOVA</method>
            <method_desc>Week 8 changes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Overactive Bladder Symptom Score According to Overactive Bladder (OAB) Awareness Tool Questionnaire at 2, 4, 8 and 12 Week</title>
        <description>Overactive bladder (OAB) Awareness Tool Questionnaire (version OAB-V8, containing 8 questions) is a validated questionnaire. Patient is asked to answer 8 questions concerning typical symptoms of OAB giving answers with a scale with minimum - 0 score defined as &quot;no bothering at all&quot; and maximmum - 5 score defined as &quot;a very big deal&quot; to assess the severity of these symptoms. All answers are simply summed to make a combined final score. Male participants should add 2 points to their final score. The final scores range from 0 to 40 (for women) and 42 (for men). The score equal to 8 and more is interpreted as high probability of OAB presence, with the higher scores indicating more bothersome symptoms of OAB.</description>
        <time_frame>Baseline and Week 2, 4, 8 and 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Overactive Bladder Symptom Score According to Overactive Bladder (OAB) Awareness Tool Questionnaire at 2, 4, 8 and 12 Week</title>
          <description>Overactive bladder (OAB) Awareness Tool Questionnaire (version OAB-V8, containing 8 questions) is a validated questionnaire. Patient is asked to answer 8 questions concerning typical symptoms of OAB giving answers with a scale with minimum - 0 score defined as &quot;no bothering at all&quot; and maximmum - 5 score defined as &quot;a very big deal&quot; to assess the severity of these symptoms. All answers are simply summed to make a combined final score. Male participants should add 2 points to their final score. The final scores range from 0 to 40 (for women) and 42 (for men). The score equal to 8 and more is interpreted as high probability of OAB presence, with the higher scores indicating more bothersome symptoms of OAB.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="7.5"/>
                    <measurement group_id="O2" value="23.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="8.2"/>
                    <measurement group_id="O2" value="-8.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="7.7"/>
                    <measurement group_id="O2" value="-10.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="8.5"/>
                    <measurement group_id="O2" value="-13.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="8.5"/>
                    <measurement group_id="O2" value="-14.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.5321</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Change week 12</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the EQ-5D-based Quality of Life at Week 12</title>
        <description>The Euro Quality of Life five Dimensions questionnaire ( EQ-5D, version EQ-5D-5L) is a validated questionnaire for the assessment of health-related quality of life. It consists of a questionnaire and a visual analogue scale (EQ-VAS). The self-assessment questionnaire is self-reported description of the subject's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The subject is asked to assess their own current level of function in each dimension by 5-level scale from &quot;no problems&quot; to &quot;significant problem&quot; grades. The EQ-VAS is a self-rated health status using a VAS in mm from 0 (the worse health status) to 100 (the best health status). The EQ-VAS records the subject's perceptions of their own current overall health quantitatively in mm and can be used to monitor changes with time. The results of patients assessment by VAS are presented.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the EQ-5D-based Quality of Life at Week 12</title>
          <description>The Euro Quality of Life five Dimensions questionnaire ( EQ-5D, version EQ-5D-5L) is a validated questionnaire for the assessment of health-related quality of life. It consists of a questionnaire and a visual analogue scale (EQ-VAS). The self-assessment questionnaire is self-reported description of the subject's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The subject is asked to assess their own current level of function in each dimension by 5-level scale from &quot;no problems&quot; to &quot;significant problem&quot; grades. The EQ-VAS is a self-rated health status using a VAS in mm from 0 (the worse health status) to 100 (the best health status). The EQ-VAS records the subject's perceptions of their own current overall health quantitatively in mm and can be used to monitor changes with time. The results of patients assessment by VAS are presented.</description>
          <population>The efficiency analysis was performed on the FAS (Full Analysis Set) population, which included all randomized patients who received at least one dose of the drug and had at least one efficiency evaluation after visit 2.</population>
          <units>score on a scale, mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="13.9"/>
                    <measurement group_id="O2" value="66.8" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="13.4"/>
                    <measurement group_id="O2" value="79.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="15.5"/>
                    <measurement group_id="O2" value="12.5" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.4839</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Change week 12</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Adverse Events (AEs)</title>
        <time_frame>Up to 35 days after the end of treatment</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events (AEs)</title>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.86</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious Adverse Events (SAEs)</title>
        <time_frame>Up to 35 days after the end of treatment</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Adverse Events (SAEs)</title>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in the Volume of Residual Urine</title>
        <description>Measured via the urine bladder ultrasound (US)</description>
        <time_frame>Baseline and Week 4, 8 and 12</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Volume of Residual Urine</title>
          <description>Measured via the urine bladder ultrasound (US)</description>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="10.2"/>
                    <measurement group_id="O2" value="10.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change week 4 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="10.9"/>
                    <measurement group_id="O2" value="-1.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change week 8 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="12.7"/>
                    <measurement group_id="O2" value="-2.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="12.6"/>
                    <measurement group_id="O2" value="-2.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Clinically Significant Changes in Laboratory Parameters</title>
        <description>Including blood chemistry, blood count and urinalysis</description>
        <time_frame>Week 8 and 12</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically Significant Changes in Laboratory Parameters</title>
          <description>Including blood chemistry, blood count and urinalysis</description>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Clinically Significant Changes in ECG Parameters</title>
        <time_frame>Week 12 of treatment</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically Significant Changes in ECG Parameters</title>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Clinically Significant Vital Signs Changes</title>
        <time_frame>Week 12 of treatment</time_frame>
        <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>Uritos®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
          </group>
          <group group_id="O2">
            <title>Urotol®</title>
            <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically Significant Vital Signs Changes</title>
          <population>Safety Population - All randomized patients taken at least one dose of investigational/reference drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 35 days after the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Uritos®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Uritos®: film-coated tablets 0.1 mg</description>
        </group>
        <group group_id="E2">
          <title>Urotol®</title>
          <description>one tablet orally twice a day (after breakfast and dinner) for 12 weeks
Urotol®: film coated tablets, 2 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="56" subjects_affected="40" subjects_at_risk="149"/>
                <counts group_id="E2" events="55" subjects_affected="45" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public available only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Georgiy Sharvadze, Medical Advisor</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937 ext 1175</phone>
      <email>sharvadze@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

